{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:35:54Z","timestamp":1786649754826,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To investigate the rate of secondary glaucoma after intravitreal (IV) dexamethasone implant (ozurdex) 0.7 mg injection in a retinal disorder over a clinical treatment period of 2 years in a tertiary eye care center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Retrospective study based on the records of patients receiving IV ozurdex 0.7 mg implant for T\/t of cystoid macular edema (CME), diabetic macular edema (DME), macular edema due to central retinal vein occlusion\/branch retinal vein occlusion (CRVO\/BRVO), and choroidal neovascular membrane (CNVM) at a tertiary eye care hospital for 2 years with 6 months of follow-up. The post-T\/t intraocular pressure (IOP) and antiglaucoma medication (AGM) required was recorded at day 1, 1 week, 1, 2, 3, 4, and 6 months and analyzed for secondary IOP spike or ocular hypertension defined as IOP &gt;21 mmHg at any point in time. The patients with pre-existing glaucoma and lost to follow-up were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 102 eyes of 80 patients were included in the study. The mean baseline IOP was 14.40 + 2.97 mmHg, post-injection was 15.01 + 3.22 mmHg at day 1, 15.15 + 3.28 mmHg at 1 week, 15.96 + 3.62 mmHg at 1 month, 16.26 + 3.95 mmHg at 2 months, 15.41 + 3.33 mmHg at 3 months, 15.38 + 3.28 mmHg at 4 months, and 14.27 + 2.69 mmHg at 6 months. No significant difference was seen from baseline IOP at day 1 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.163), 1 week (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.086), and 6 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.748). Statistically significant difference was seen at 1 month (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0009), 2 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0001), 3 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.023), and 4 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.026). The mean IOP peak at 2 months recovered to baseline by 6 months subgroup IOP trend shows a similar variation and the results are consistent with the studies in the literature. About 19\/102 (18.62%) eyes showed an IOP spike post-T\/t. The maximum was seen at 2 months; 16 eyes showed a rise in the range 22\u201325 mmHg; 8 in the range 26\u201330 mmHg; and 1 eye had 34 mmHg and required multiple AGM\u2014no surgical intervention was needed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>A secondary IOP spike post-IV ozurdex 0.7 mg seen in 18.62% of the cases require AGM. The IOP monitoring should be meticulously performed for the variations and secondary IOP spike management to prevent irreversible damage to the optic nerve and visual field.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_684_21","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T07:51:02Z","timestamp":1644997862000},"page":"585-589","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Secondary glaucoma after intravitreal dexamethasone implant (Ozurdex) injection in patients with retinal disorder: A retrospective study"],"prefix":"10.4103","volume":"70","author":[{"given":"VD","family":"Sweta","sequence":"first","affiliation":[{"name":"Department of Glaucoma, Nethradhama Superspeciality Eye Hospital, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BN","family":"Shibi Dev","sequence":"additional","affiliation":[{"name":"Department of Glaucoma, Nethradhama Superspeciality Eye Hospital, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Sandhya","sequence":"additional","affiliation":[{"name":"Department of Glaucoma, Nethradhama Superspeciality Eye Hospital, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"R1-20251006","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00417-006-0514-0","article-title":"Intravitreal triamcinolone acetonide in the management of cystoid macular edema in behcet's disease","volume":"245","author":"Atmaca","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R2-20251006","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archopht.126.9.1191","article-title":"Treatment of posterior uveitis with a fluocinolone acetonide implant:Three-year clinical trial results","volume":"126","author":"Callanan","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"R3-20251006","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.ophtha.2007.02.013","article-title":"Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration:A prospective randomized trial","volume":"114","author":"Chaudhary","year":"2007","journal-title":"Ophthalmology"},{"key":"R4-20251006","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/00006982-200510000-00002","article-title":"Intravitreal triamcinolone acetonide for diabetic macular edema","volume":"25","author":"Chieh","year":"2005","journal-title":"Retina"},{"key":"R5-20251006","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"R6-20251006","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","article-title":"Fluocinolone acetonide implant (retisert) for non-infectious posterior uveitis:Thirty-four-week results of a multicenter randomized clinical study","volume":"113","author":"Jaffe","year":"2006","journal-title":"Ophthalmology"},{"key":"R7-20251006","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"R8-20251006","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/bjo.2006.090340","article-title":"Intraocular pressure alterations following intravitreal triamcinolone acetonide","volume":"90","author":"Rhee","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R9-20251006","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/archopht.125.11.ecs70063","article-title":"Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants","volume":"125","author":"Goldstein","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R10-20251006","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/jop.2012.0180","article-title":"A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis","volume":"29","author":"Arcinue","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"R11-20251006","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/IAE.0b013e318206d18c","article-title":"Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients","volume":"31","author":"Boyer","year":"2011","journal-title":"Retina"},{"key":"R12-20251006","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/IAE.0b013e318188c814","article-title":"Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema","volume":"29","author":"Haller","year":"2009","journal-title":"Retina"},{"key":"R13-20251006","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archophthalmol.2010.21","article-title":"Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema","volume":"128","author":"Haller","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"R14-20251006","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"R15-20251006","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.survophthal.2012.08.003","article-title":"Intraocular pressure monitoring post intravitreal steroids:A systematic review","volume":"58","author":"Kiddee","year":"2013","journal-title":"Surv Ophthalmol"},{"key":"R16-20251006","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00061198-199510000-00010","article-title":"Basic sciences in clinical glaucoma:Steroids, ocular hypertension, and glaucoma","volume":"4","author":"Clark","year":"1995","journal-title":"J Glaucoma"},{"key":"R17-20251006","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/IAE.0b013e31816079e8","article-title":"Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide:Incidence and risk factors","volume":"28","author":"Vasconcelos-Santos","year":"2008","journal-title":"Retina"},{"key":"R18-20251006","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ajo.2004.06.067","article-title":"Intravitreal triamcinolone acetonide and intraocular pressure","volume":"138","author":"Smithen","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R19-20251006","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ophtha.2008.10.002","article-title":"Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection","volume":"116","author":"Roth","year":"2009","journal-title":"Ophthalmology"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_684_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:58:02Z","timestamp":1786647482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_684_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_684_21","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"2021-03-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}